Development of a guideline for the management of ventilator-associated pneumonia based on local microbiologic findings and impact of the guideline on antimicrobial use practices

Infection Control and Hospital Epidemiology

Volumn 29, Issue 6, 2008, Pages 525-533

  Dellit, Timothy H ^a,b   Chan, Jeannie D ^a,b   Skerrett, Shawn J ^a,b   Nathens, Avery B ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CEFTRIAXONE; ERTAPENEM; IMIPENEM; MEROPENEM; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN;

ACINETOBACTER; ADOLESCENT; ADULT; AGED; ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BRONCHOSCOPY; CLINICAL PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BRONCHOSCOPY; GUIDELINE ADHERENCE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATION, ARTIFICIAL;

EID: 46349086469     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/588160     Document Type: Article

References (13)

1. American Thoracic Society and Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
2. Chastre J, Tagon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
3. Rello J, Ollendorf DA, Oster G, et al. H. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115-2121.
4. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474.
5. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121-1129.
6. Fagon J-Y, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. Ann Intern Med 2000;132:621-630.
7. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empirical antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med 2000;162:505-511.
8. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001;29:1109-1115.
9. Chastre J, Wolff M, Fagon J-Y. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003;290:2588-2598.
10. Knaus WA, Wagner DP, Draper EA, et al. The APACHE II prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991;100:1619-1636.
11. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(suppl 4):S131-138.
12. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. BMJ 2004;328:668.
13. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005;41:149-158.